Cipher Pharmaceuticals (TSE:CPH) Releases Quarterly Earnings Results

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) posted its quarterly earnings results on Thursday. The company reported C$0.60 earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of C$18.08 million for the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%.

Cipher Pharmaceuticals Stock Performance

CPH traded down C$0.11 on Thursday, hitting C$13.61. The company’s stock had a trading volume of 22,641 shares, compared to its average volume of 28,854. The company’s 50 day simple moving average is C$13.79 and its 200-day simple moving average is C$15.74. The firm has a market cap of C$345.90 million, a P/E ratio of 12.15 and a beta of 1.29. Cipher Pharmaceuticals has a 12 month low of C$12.76 and a 12 month high of C$20.56. The company has a quick ratio of 2.67, a current ratio of 1.59 and a debt-to-equity ratio of 0.27.

Insiders Place Their Bets

In other Cipher Pharmaceuticals news, Director Craig Mull bought 20,000 shares of the stock in a transaction on Friday, September 18th. The shares were acquired at an average price of C$14.16 per share, with a total value of C$283,200.00. Following the acquisition, the director directly owned 1,009,953 shares of the company’s stock, valued at C$14,300,934.48. The trade was a 2.02% increase in their position. Corporate insiders own 42.00% of the company’s stock.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.